MDMA Files Comments on IPPS Proposed Rule
June 30, 2009 - MDMA filed comments this week on the Medicare Inpatient Prospective Payment System Proposed rule. MDMA’s comments focused on improving access to New-Technology payments and ensuring adequate reimbursement for medical technologies in the inpatient setting. Read more…

Health Care Reform Delayed in Senate
June 16, 2009 - The Senate Committee on Finance, the chief negotiating committee for health care reform this year, delayed the release of details on broad based health care reform this week. The delay comes after the Congressional Budget Office (CBO) provided cost estimates to the Committee. According to the CBO, the proposed Finance Committee plan to expand coverage and make other changes to the health care system would cost approximately $1.6 trillion over 10 years. The Committee has delayed the release of its plan until early July while it works to reduce the cost of the legislation by $600 billion. Read More

SBIR Legislation Introduced in the Senate
June 12, 2009 - Legislation was introduced this week that would reauthorize the Small Business Administration's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) programs. MDMA is currently reviewing the Senate legislation and will continue to advocate that any legislation to reauthorize the SBIR program includes language that adequately addresses the SBA restriction on venture-owned firms competing for grants.

2009 MDMA Annual Meeting Huge Success

June 4, 2009 - With a record turnout of nearly 175 medical technology executives and professionals, the 2009 MDMA Annual Meeting was a huge success.

The meeting provided an opportunity for attendees to hear and discuss some of the most critical issues of concern to device manufacturers within the current legislative and regulatory environment.
Read the meeting recap

Massachusetts Issues Guidance on Device Manufacturer Conduct
May 28, 2009 - The Massachusetts Department of Public Health (MDPH) issued guidance on the recently implemented pharmaceutical and medical device manufacturer conduct regulations. MDMA is pleased that MDPH clarified that the regulations do not apply to pre-commercial companies. Furthermore, companies without disclosure filings do not have to pay the required $2,000 fee. However, they do require any company interacting with a Massachusetts licensed health care practitioners with prescribing authority to comply with the new requirements. Read More

Other Recent Headlines

Senate Confirms Hamburg as FDA Commissioner

Administration Releases FY 2010 Budget Proposal

CMS Reduces Hospital Payments in FY 2010 IPPS Proposed Rule

Panel Examines Device Preemption Bill

Weigh in on these important issues, visit the MDMA Legislative Action Center.